PPARG and hepatocellular carcinoma: Butsome studies have contrasting results that the PPARγ, ciglitazone, induced cell invasion, throughactivation of Pro-MMP-2, activation via the generation of ROS, and the activationof ERK [19], and that PPARγ antagonists induced vimentin cleavage and inhibitedinvasion in high-grade hepatocellular carcinoma [20].